Table 1.

Baseline demographics and clinicopathological characteristics of all patients (metastatic and non-metastatic groups)

Characteristic	All patients(N = 1160, 100%) Number (%)	Non-metastatic(N = 844, 72.8%) Number (%)	Metastatic(N = 316, 27.2%) Number (%)	p value
Age (years)				0.011*
≤ 10	242 (20.9%)	197 (23.3%)	45 (14.2%)
11–20	571 (49.2%)	402 (47.6%)	169 (53.5%)
21–30	206 (17.8%)	142 (16.8%)	64 (20.3%)
31-49	101 (8.7%)	76 (9.0%)	25 (7.9%)
≥ 50	40 (3.4%)	27 (3.2%)	13 (4.1%)
Gender				0.926
Male	733 (63.2%)	534 (63.3%)	199 (63.0%)
Female	427 (36.8%)	310 (36.7%)	117 (37.0%)
Race				0.749
White	1041 (89.7%)	759 (89.9%)	282 (89.2%)
Black	30 (2.6%)	20 (2.4%)	10 (3.2%)
Other*	89 (7.7%)	65 (7.7%)	24 (7.6%)
Primary site				< 0.001***
Limb	519 (44.7%)	405 (48.0%)	114 (36.1%)
Cranial	66 (5.7%)	60 (7.1%)	6 (1.9%)
Spine	88 (7.6%)	71 (8.4%)	17 (5.4%)
Thoracic	173 (14.9%)	129 (15.3%)	44 (13.9%)
Pelvic	314 (27.1%)	179 (21.2%)	135 (42.7%)
Tumor size (cm)				< 0.001***
< 5	221 (19.1%)	185 (21.9%)	36 (11.4%)
5–8	371 (32.0%)	283 (33.5%)	88 (27.8%)
> 8	568 (49.0%)	376 (44.5%)	192 (60.8%)
Tumor extent				-
Localized	311 (26.8%)	311 (36.8%)	0 (0.0%)
Regional	533 (45.9%)	533 (63.2%)	0 (0.0%)
Metastatic	316 (27.2%)	0 (0.0%)	316 (100.0%)
Cancer-directed surgery				< 0.001***
No	390 (33.6%)	213 (25.2%)	177 (54.0%)
Yes	770 (66.4%)	631 (74.8%)	139 (44.0%)
Radiation				< 0.001***
No	584 (50.3%)	468 (55.5%)	116 (36.7%)
Yes	576 (49.7%)	376 (44.5%)	200 (63.3%)
Chemotherapy				0.49
No	40 (3.4%)	31 (3.7%)	9 (2.8%)
Yes	1120 (96.6%)	813 (96.3%)	307 (97.2%)

p value < 0.05*, < 0.001***

*Including Native American/Alaska Native, Asian/Pacific Islander